Novartis Patient Support is a comprehensive program that is designed to help your eligible patients start, stay, and save on RHAPSIDO^® (remibrutinib)

Get your patients started on RHAPSIDO:

Insurance support

Help navigating the insurance process, including benefits verification and support with the prior authorization and appeals processes.

Benefits verification

Once you’ve enrolled your patients in Novartis Patient Support, our team will conduct a benefits verification to better understand your patient’s coverage, including:

• Informing your practice about additional requirements, such as prior authorization

• Identifying savings options available to your patients

Prior authorizations (PAs) and appeals

Novartis Patient Support can help with PA requests or letters of appeal by working directly with you or your office, including:

• Providing helpful information and timely updates via phone

• Providing a PA and Appeals Kit and ICD-10 flashcard

Financial support

Assist with connecting patients to relevant savings options.

At Novartis Patient Support, we understand that affordability is important. That’s why we offer a range of savings options and resources to help your patients access treatment regardless of their ability to pay.

To sign up for the $0 Co-Pay Plus offer*:

Up to 12 months of RHAPSIDO for free. Eligible patients whose insurance coverage is delayed or denied can start treatment while health plan coverage is pursued. 

To be eligible for both offers, patients must have:

• Private insurance 

• A valid prescription for RHAPSIDO 

• Additional terms apply

*Limitations apply. Valid only for those with private insurance. The Program includes the Co-Pay Plus offer, Plus Card (if applicable), and Rebate, with a combined annual limit. Patient is responsible for any costs once limit is reached in a calendar year. Program not valid (i) under Medicare, Medicaid, TRICARE, VA, DoD, or any other federal or state health care program, (ii) where patient is not using insurance coverage at all, (iii) where the patient’s insurance plan reimburses for the entire cost of the drug, or (iv) where product is not covered by patient’s insurance. The value of this program is exclusively for the benefit of patients and is intended to be credited toward patient out-of-pocket obligations and maximums, including applicable co-payments, coinsurance, and deductibles. Program is not valid where prohibited by law. Patient may not seek reimbursement for the value received from this program from other parties, including any health insurance program or plan, flexible spending account, or health care savings account. Patient is responsible for complying with any applicable limitations and requirements of their health plan related to the use of the Program. Valid only in the United States and Puerto Rico. This Program is not health insurance. Program may not be combined with any third-party rebate, coupon, or offer. Proof of purchase may be required. Novartis reserves the right to rescind, revoke, or amend the Program and discontinue support at any time without notice.
^†The Bridge Program applies to RHAPSIDO^® only. Eligible patients must have private insurance and a valid prescription for RHAPSIDO, and a delay or denial of coverage. Program requires the submission of a prior authorization or an appeal of the coverage denial within the first 90 days of enrollment to remain eligible. Program provides RHAPSIDO for free to eligible patients for up to 12 months, or until they receive insurance coverage approval, whichever occurs earlier. A valid prescription consistent with FDA-approved labeling is required. Program is not available to patients whose medications are reimbursed in whole or in part by Medicare, Medicaid, TRICARE, or any other federal or state program. Patients may be asked to reverify insurance coverage status during the course of the program. No purchase necessary. Program is not health insurance, nor is participation a guarantee of insurance coverage. Additional limitations may apply. Novartis Pharmaceuticals Corporation reserves the right to rescind, revoke, or amend this Program without notice.

Novartis Patient Support provides patients with ongoing help to stay on track with their RHAPSIDO treatment plan, including:

• A dedicated Novartis Patient Support Team member to answer their questions at every step

• Help navigating health care changes

• Tips for setting up a routine that helps keep them on track with their medication dosing via their choice of texts, calls, or emails

• Resources for finding supportive communities

Learn more about Novartis Patient Support offerings within the Patient Brochure.

Novartis Patient Support does not provide clinical advice or care and is not a substitute for patient consultation with a health care provider.

The Novartis Patient Assistance Foundation, Inc. (NPAF) is an independent, 501(c)(3) nonprofit entity that provides certain medications at no cost to eligible patients who cannot afford the cost of Novartis medications supported by NPAF. 

Patients may be eligible for NPAF support if they:

• Are a resident of the U.S. or its territories

• Are prescribed a product on the NPAF formulary

• Meet NPAF income eligibility requirements

• Are uninsured or are a qualifying patient with government insurance who cannot afford their out-of-pocket costs and, in the case of Medicare patients, do not qualify for Medicare’s Extra Help Program (Low Income Subsidy)

NPAF does not provide product to individuals having insurance associated with any type of alternative funding program that conditions, restricts, or adjusts coverage based on application to NPAF or to any other free goods program. To receive support through NPAF, applicants must submit all required documentation, including proof of income and evidence of Extra Help denial as deemed necessary. Only the patient or their legal guardian or caregiver may enroll the patient in the program. Health plans, specialty pharmacies, pharmacy benefit managers, and their agents and representatives are prohibited from enrolling patients in the program. Novartis Patient Assistance Foundation, Inc., at its sole and absolute discretion, reserves the right to modify or discontinue the program at any time and to verify the accuracy of enrollment information submitted. Please visit www.PAP.Novartis.com for more information.